Mount Sinai Hospital: First Oral Medication to Treat Moderate-to-Severe Crohn's Disease Completes Successful Phase 3 Trial and Earns FDA Approval
May 27, 2023
May 27, 2023
NEW YORK, May 27 (TNSjou) -- Mount Sinai Hospital issued the following news release on May 25, 2023:
Patients with moderate-to-severe Crohn's disease now have a new treatment option to suppress their intestinal inflammation and painful symptoms, and help them maintain their relief.
Data from a phase 3 trial published today in The New England Journal of Medicine show that upadacitinib--a breakthrough, once-daily oral medication--helps patients achieve and maintain c . . .
Patients with moderate-to-severe Crohn's disease now have a new treatment option to suppress their intestinal inflammation and painful symptoms, and help them maintain their relief.
Data from a phase 3 trial published today in The New England Journal of Medicine show that upadacitinib--a breakthrough, once-daily oral medication--helps patients achieve and maintain c . . .